How Does Prostate Cancer Metastasize? Studying the Role of Secreted Packages (Exosomes) From Fat Tissue in Lean and Obese Patients

Overview

The investigators will be collecting prostate and fat tissue from participants undergoing radical prostatectomy to culture and study in the laboratory.

Full Title of Study: “The EXOPRO Study: How Does Prostate Cancer Metastasize? Understanding the Role of Exosomal Communication in Lean vs Obese Patients”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 1, 2023

Detailed Description

Both obesity and prostate cancer are major health problems in the UK, affecting 1 in 3 and 1 in 8 men respectively. Moreover, obesity increases the risk of developing aggressive disease and the risk of prostate cancer spreading. How this happens is not known. The investigators want to understand how fat cells communicate with prostate cancer cells. Investigators will be collecting prostate and fat tissue from radical prostatectomy participants for culture, in particular to look at exosome communication.

Interventions

  • Procedure: Robotic Radical Prostatectomy
    • Routine NHS Radical Prostatectomy

Arms, Groups and Cohorts

  • Obese patients
    • BMI > 25
  • Lean patients
    • BMI < or = 25

Clinical Trial Outcome Measures

Primary Measures

  • Determine functional differences of peri-prostatic adipose tissue from lean vs obese patients on prostate cancer cell lines
    • Time Frame: Through to study completion, on average 3 years
    • Proliferation, migration, invasion, apoptosis and epthelial-mesenchymal transition assays will be performed using isolated exosomes on prostate cancer cell lines
  • Identification of exosomal small RNAs transferred between human adipose tissue to prostate cancer cells lines
    • Time Frame: Through to study completion, on average 3 years
    • Exosomal RNA transferred from human adipose tissue to prostate cancer cell lines will be isolated using a tagged magnetic bead isolation method and sequenced to identify transferred small RNAs
  • Assess how exosomal small RNAs from lean vs obese patients affect cancer regulation
    • Time Frame: Through to study completion, on average 3 years
    • Prostate cancer cell lines will be treated with isolated exosomes, then parental and treated cells sequenced to identify differentially expressed RNA and underlying changes
  • Attempt to replicate functional changes observed
    • Time Frame: Through to study completion, on average 3 years
    • Treatment of prostate cancer cell lines with microRNA mimics or inhibitors and comparison of changes with exosome treated cell lines

Participating in This Clinical Trial

Inclusion Criteria

  • All men undergoing radical prostatectomy at Charing Cross Hospital Exclusion Criteria:

  • Patients unable to consent

Gender Eligibility: Male

Biological male only (can include transgender women)

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Imperial College London
  • Collaborator
    • Imperial College Healthcare NHS Trust
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Charlotte Bevan, PhD, Principal Investigator, Imperial College London
    • Mathias Winkler, FRCS, Principal Investigator, Imperial College Healthcare NHS Trust
  • Overall Contact(s)
    • Joseph Tam, MBBCh, +442075942135, j.tam18@imperial.ac.uk

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.